{"content":"<li class=\"n-box-item date-title\" data-end=\"1506484799\" data-start=\"1506398400\" data-txt=\"Monday, December 23, 2019\">Tuesday, September 26, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3297750\" data-ts=\"1506470231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIX\" target=\"_blank\">SIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297750-gaining-on-s-and-p-index-changes-six-stl-kem\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gaining on S&amp;P index changes: SIX, STL, KEM</a></h4><ul>   <li>Six Flags Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/SIX' title='Six Flags Entertainment Corporation'>SIX</a>) is <font color='green'>up 3.1%</font> after hours on word that it's <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/590349_sixbanks46.pdf?force_download=true\" target=\"_blank\">moving into the S&amp;P MidCap 400</a>, there to replace Parexel International (NASDAQ:<a href='https://seekingalpha.com/symbol/PRXL' title='PAREXEL International Corporation'>PRXL</a>), which is set to be acquired by Pamplona Capital Management.</li>    <li>In other after-hours moves tied to index changes, Sterling Bancorp (NYSE:<a href='https://seekingalpha.com/symbol/STL' title='Sterling Bancorp'>STL</a>) -- currently part of the SmallCap 600 -- head up to the MidCap 400, trading places with Oil States International (NYSE:<a href='https://seekingalpha.com/symbol/OIS' title='Oil States International Inc.'>OIS</a>), which S&amp;P says is now more representative of the small-cap space. <a href='https://seekingalpha.com/symbol/STL' title='Sterling Bancorp'>STL</a> is <font color='green'>up 1%</font> after hours.</li>    <li>Meanwhile, Kemet (NYSE:<a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a>) is <font color='green'>up 4.6%</font> in late trading as it's going into the SmallCap 600 to replace Astoria Financial (NYSE:<a href='https://seekingalpha.com/symbol/AF' title='Astoria Financial Corporation'>AF</a>), which is being acquired by Sterling Bancorp.</li>    <li>All moves are effective prior to the open on Monday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297750\" data-linked=\"Gaining on S&amp;P index changes: SIX, STL, KEM\" data-tweet=\"$SIX $SIX $PRXL - Gaining on S&amp;P index changes: SIX, STL, KEM https://seekingalpha.com/news/3297750-gaining-on-s-and-p-index-changes-six-stl-kem?source=tweet\" data-url=\"https://seekingalpha.com/news/3297750-gaining-on-s-and-p-index-changes-six-stl-kem\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297749\" data-ts=\"1506469666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBNT\" target=\"_blank\">UBNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297749-ubiquiti-networks-slips-during-eventful-investor-day-defense\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ubiquiti Networks slips during eventful investor-day defense</a></h4><ul>   <li>Ubiquiti Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/UBNT' title='Ubiquiti Networks, Inc.'>UBNT</a>) shares declined during today's investor day presentation to finish <font color='red'>2.9% lower</font>, as CEO/Chairman Robert Pera faced <a href=\"http://www.marketwatch.com/story/ubiquiti-shares-finish-lower-after-ceos-spirited-defense-at-investor-day-2017-09-26\" target=\"_blank\">questions about the company's governance</a> and on recent claims from short-sellers.</li>    <li>Why doesn't the company have an official chief financial officer? \"Maybe I should have just called [Kevin Radigan] CFO so everybody would shut up,&rdquo; Pera said about his chief accounting officer. &ldquo;CAO, CFO, whatever you want to call it, he&rsquo;s in charge of the finances, he signs the books.\"</li>    <li>Buybacks of a depressed stock at \"fractions of a dollar\" are good for the company and helps a \"long-term goal of increasing EPS,\" he says.</li>    <li>The stock had hit an all-time high after <a href=\"https://seekingalpha.com/news/3285339-ubiquiti-networks-plus-24-percent-new-high-record-revenues\" target=\"_blank\">earnings Aug. 3</a> and built on that over the next few weeks, but shares slid a week ago after a Citron Research short report <a href=\"https://seekingalpha.com/news/3296039-ubiquiti-networks-fraud-claims-citron-research\" target=\"_blank\">calling the company a fraud</a>.</li>    <li>Citron (an SA contributor) this morning posted a <a href=\"https://seekingalpha.com/article/4109414-questions-ubiquitis-ceo-investor-day\" target=\"_blank\">series of questions</a> for the investor day, saying \"This story is far from over and probably just getting started.\" Among those: Questions about the slow growth of cash balances, and \"Accepting that the company has a misunderstood business model, do you plan on breaking out products and segments so the Street can have more clarity into your business and understand where the margins are being generated?\"</li>    <li>Speaking to some of company's structural changes, Pera said today &ldquo;The inventory centers were a step in the right direction ... I don&rsquo;t think our operations in general have been very good.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297749\" data-linked=\"Ubiquiti Networks slips during eventful investor-day defense\" data-tweet=\"$UBNT $UI - Ubiquiti Networks slips during eventful investor-day defense https://seekingalpha.com/news/3297749-ubiquiti-networks-slips-during-eventful-investor-day-defense?source=tweet\" data-url=\"https://seekingalpha.com/news/3297749-ubiquiti-networks-slips-during-eventful-investor-day-defense\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297741\" data-ts=\"1506464244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGR\" target=\"_blank\">AVGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297741-avinger-wins-ce-marking-approval-for-in-stent-restenosis-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avinger wins CE Marking approval for in-stent restenosis treatment</a></h4><ul>     <li>Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a>) <font color='green'>+128.6%</font> AH on news it <a href=\"https://seekingalpha.com/pr/16951834-avinger-receives-ce-marking-approval-stent-restenosis-treatment-indication-pantheris-image\" target=\"_blank\">received CE Marking approval</a> for treating in-stent restenosis with its Pantheris Lumivascular atherectomy system.</li>     <li>AVGR's lumivascular platform offers real-time visualization of the inside of the artery during treatment of peripheral artery disease, and consists of the Lightbox imaging console, the Ocelot family of chronic  total occlusion catheters and the Pantheris family of  atherectomy devices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297741\" data-linked=\"Avinger wins CE Marking approval for in-stent restenosis treatment\" data-tweet=\"$AVGR - Avinger wins CE Marking approval for in-stent restenosis treatment https://seekingalpha.com/news/3297741-avinger-wins-ce-marking-approval-for-in-stent-restenosis-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3297741-avinger-wins-ce-marking-approval-for-in-stent-restenosis-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297738\" data-ts=\"1506463462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WLKP\" target=\"_blank\">WLKP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297738-westlake-chemical-partners-buys-added-stake-in-westlake-opco-for-229m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westlake Chemical Partners buys added stake in Westlake OpCo for $229M</a></h4><ul>     <li>Westlake Chemical Partners (NYSE:<a href='https://seekingalpha.com/symbol/WLKP' title='Westlake Chemical Partners LP'>WLKP</a>) <font color='red'>-8.3%</font> AH after <a href=\"https://seekingalpha.com/pr/16951859-westlake-chemical-partners-lp-acquires-additional-interest-westlake-chemical-opco\" target=\"_blank\">agreeing to acquire</a> an additional 5% limited partner interest in Westlake Chemical OpCo for ~$229M, raising its stake to 18.3%.</li>     <li>OpCo&rsquo;s assets include three ethylene production facilities with total annual capacity of ~3.7B lbs. and a 200-mile ethylene pipeline, and the company sells 95% of its ethylene production to Westlake Chemical (NYSE:<a href='https://seekingalpha.com/symbol/WLK' title='Westlake Chemical Corporation'>WLK</a>) under a long-term supply agreement.</li>     <li>To help fund the deal, WLKP commences a 4.5M-unit <a href=\"https://seekingalpha.com/pr/16951860-westlake-chemical-partners-lp-announces-offering-common-units\" target=\"_blank\">public offering</a>, with an underwriters option to purchase up to an additional 675K common units.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297738\" data-linked=\"Westlake Chemical Partners buys added stake in Westlake OpCo for $229M\" data-tweet=\"$WLKP $WLKP $WLK - Westlake Chemical Partners buys added stake in Westlake OpCo for $229M https://seekingalpha.com/news/3297738-westlake-chemical-partners-buys-added-stake-in-westlake-opco-for-229m?source=tweet\" data-url=\"https://seekingalpha.com/news/3297738-westlake-chemical-partners-buys-added-stake-in-westlake-opco-for-229m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297735\" data-ts=\"1506461763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297735-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/CEMP' title='Cempra, Inc.'>CEMP</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/UCTT' title='Ultra Clean Holdings, Inc.'>UCTT</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/CTAS' title='Cintas Corporation'>CTAS</a> <font color='green'>+2.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='red'>-7.2%</font>. <a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/IMKTA' title='Ingles Markets, Incorporated'>IMKTA</a> <font color='red'>-2.8%</font>. <a href='https://seekingalpha.com/symbol/CARB' title='Carbonite Inc.'>CARB</a> <font color='red'>-2.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297735\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CEMP $USAT $EDIT - After Hours Gainers / Losers https://seekingalpha.com/news/3297735-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3297735-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297728\" data-ts=\"1506460128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297728-twitters-latest-tweak-doubling-tweet-sizes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter&#39;s latest tweak: Doubling tweet sizes</a></h4><ul>   <li>Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='red'>-2.3%</font>) -- fighting a tough battle with Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='green'>+0.8%</font>) for hearts and minds of social-media users -- is tweaking another part of its interface that some considered a handicap in that fight, by stretching its venerable 140-character tweet limit.</li>    <li>The company is <a href=\"http://adage.com/article/digital/140-characters-a-quirk-twitter-a-relic-past/310632/\" target=\"_blank\">expanding tweets to 280 characters</a>, double the original size, starting with a subset of users.</li>    <li>Twitter had hinted at the change before, and it's the latest in a series of mild interface tweaks that come even as company critics urge stronger changes amid criticism of violent and harassing content on the platform.</li>    <li>But the 140-character limit (itself a vestige of early phone texting limits) had come to signify a hurdle in drawing users from competing platforms who weren't used to hitting a wall in putting their thoughts online.</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a> <font color='green'>+1.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297728\" data-linked=\"Twitter&#39;s latest tweak: Doubling tweet sizes\" data-tweet=\"$TWTR $TWTR $FB - Twitter&#39;s latest tweak: Doubling tweet sizes https://seekingalpha.com/news/3297728-twitters-latest-tweak-doubling-tweet-sizes?source=tweet\" data-url=\"https://seekingalpha.com/news/3297728-twitters-latest-tweak-doubling-tweet-sizes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297722\" data-ts=\"1506459282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297722-micron-technologyplus-2-after-q4-guidance-beats-on-strong-dram-and-nand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology +2% after Q4, guidance beats on strong DRAM and NAND</a></h4><ul><li>        Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) shares are&nbsp;<font color='green'>up 2%</font>&nbsp;aftermarket following Q4 beats on strong NAND and DRAM performance and guidance that exceeds consensus estimates.</li><li>               Q1 guidance: $6.1B to $6.5B (consensus:$6.06B); gross margin, 50% to 54%; operating expenses, $575M to $625M; operating income, $2.65B to $2.85B; EPS, $2.09 to $2.23 (consensus: $1.85).&nbsp;</li><li>Unit sales: Compute &amp; Networking, $2.85B (+128% Y/Y); Mobile, $1.18B (+ 76%); Storage, $1.3B (+72%); Embedded, $827M (+61%).&nbsp;               </li><li>DRAM sales volumes were up 5% on the year and average selling prices were up 8%. DRAM represented 66% of total Micron revenue in Q4 with Server DRAM making up the highest percentage at 30%. The company expects DRAM industry supply bit growth of 20% in both CY17 and CY18 due to moderate undersupplies.&nbsp;</li><li>        NAND revenue presented 30% of total sales with sales volumes up 3% and ASPs up 5%. SSD, Mobile, and Automotive, Industrial, and Other tied at 20% shares of the NAND sales. Micron expects NAND sales to grow in the high 30% range in CY17 and nearly 50% growth in CY18 due to constricted supplies and booming demand.&nbsp;</li><li>               Financials: Gross margin was 51% compared to 18.6% in last year&rsquo;s quarter.&nbsp; Operating income was $2.5B and operating expenses totaled $610M. SG&amp;A spending was up 25% to $193M while R&amp;D spending rose 9% to $447M. Micron ended the quarter with $5.4B in cash and equivalents. &nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16951821-micron-technology-inc-reports-results-fourth-quarter-full-year-2017\" target=\"_blank\">Press release</a> / <a href=\"http://files.shareholder.com/downloads/ABEA-45YXOQ/5283662275x0x957974/3BB951B0-56C6-4C68-AB51-3A278890ABAE/Micron_FQ4-2017_Earnings_Call_Presentation_Slides_Website.pdf\" target=\"_blank\">Earnings slides</a>&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297691-micron-technology-beats-0_18-beats-revenue\" target=\"_blank\">Micron Technology beats by $0.18, beats on revenue</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297722\" data-linked=\"Micron Technology +2% after Q4, guidance beats on strong DRAM and NAND\" data-tweet=\"$MU - Micron Technology +2% after Q4, guidance beats on strong DRAM and NAND https://seekingalpha.com/news/3297722-micron-technologyplus-2-after-q4-guidance-beats-on-strong-dram-and-nand?source=tweet\" data-url=\"https://seekingalpha.com/news/3297722-micron-technologyplus-2-after-q4-guidance-beats-on-strong-dram-and-nand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>105&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297721\" data-ts=\"1506458884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FWP\" target=\"_blank\">FWP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297721-forward-pharma-h1-top-line-1_25b-on-biogen-settlement-eps-1_91-shares-up-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forward Pharma H1 top line $1.25B on Biogen settlement, EPS $1.91; shares up 5% after hours</a></h4><ul><li>Forward Pharma A/S (NASDAQ:<a href='https://seekingalpha.com/symbol/FWP' title='Forward Pharma'>FWP</a>) <a href=\"https://seekingalpha.com/pr/16951875-forward-pharma-reports-financial-operational-results-first-six-months-2017\" target=\"_blank\">H1 results</a> ($M): Revenue (Biogen settlement): $1,250.0; Net Income: 1,213.0; EPS: 1.91.</li><li>In July, co. distributed 917.7M euros to shareholders and executed a 10:1 split of its ordinary shares.</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297721\" data-linked=\"Forward Pharma H1 top line $1.25B on Biogen settlement, EPS $1.91; shares up 5% after hours\" data-tweet=\"$FWP - Forward Pharma H1 top line $1.25B on Biogen settlement, EPS $1.91; shares up 5% after hours https://seekingalpha.com/news/3297721-forward-pharma-h1-top-line-1_25b-on-biogen-settlement-eps-1_91-shares-up-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3297721-forward-pharma-h1-top-line-1_25b-on-biogen-settlement-eps-1_91-shares-up-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297717\" data-ts=\"1506458448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KRNT\" target=\"_blank\">KRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297717-kornit-digital-lowers-revenue-guidance-shares-flat-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kornit Digital lowers revenue guidance; shares flat AH</a></h4><ul>     <li>Kornit Digital  (NASDAQ:<a href='https://seekingalpha.com/symbol/KRNT' title='Kornit Digital'>KRNT</a>) <a href=\"https://seekingalpha.com/pr/16951887-kornit-digital-reports-preliminary-results-third-quarter-2017\" target=\"_blank\">now expects</a> Non-GAAP revenue in Q3 to be in a range of ~$27M - $28.5M vs. a consensus of $36.13M and prior guidance range of $34M - $38M.</li>     <li>Non-GAAP operating margin to be in a range of 3.0% to 5.0% of non-GAAP revenue, compared with its previously disclosed Q3 guidance of 13.0% to 17.0%.</li>     <li>CEO Gabi Seligsohn: &ldquo;We are disappointed in the further delay of a key customer's site launch which caused a significant reduction in our quarterly revenues. At the same time, this important customer remains committed to the Kornit platform and we stand ready to execute on the program when site permit issues abate. This issue notwithstanding, our underlying business continues to grow and we continue to drive meaningful progress in achieving our strategic objectives. During the third quarter we added two new Vulcan customers, received an order for multiple Storm Hexa systems from a leading Chinese e-commerce player and continued to increase sales of upgrades, bringing us close  to our targeted breakeven point in our services business.  I am confident that our strategy will allow us to continue to lead the DTG market as well as expand our position in the roll-to-roll market at a time when digital printing is enabling an online revolution.&rdquo;</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3297717\" data-linked=\"Kornit Digital lowers revenue guidance; shares flat AH\" data-tweet=\"$KRNT - Kornit Digital lowers revenue guidance; shares flat AH https://seekingalpha.com/news/3297717-kornit-digital-lowers-revenue-guidance-shares-flat-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3297717-kornit-digital-lowers-revenue-guidance-shares-flat-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297705\" data-ts=\"1506457213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297705-editas-meds-editminus-101-orphan-drug-in-europe-for-lca10-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Editas Med&#39;s EDIT-101 an Orphan Drug in Europe for LCA10; shares up 2% after hours</a></h4><ul><li>The European Medicines Agency <a href=\"https://seekingalpha.com/pr/16951832-editas-medicine-receives-ema-s-orphan-medicinal-product-designation-editminus-101-treatment\" target=\"_blank\">designates </a>Editas Medicine's (NASDAQ:<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a>) EDIT-101 an Orphan Drug for the treatment of LCA10, an inherited disorder characterized by childhood blindness. An IND is on tap for mid-2018.</li><li>Among the benefits of Orphan Drug status in Europe is a ten-year period of market exclusivity for the indication, if approved.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297705\" data-linked=\"Editas Med&#39;s EDIT-101 an Orphan Drug in Europe for LCA10; shares up 2% after hours\" data-tweet=\"$EDIT - Editas Med&#39;s EDIT-101 an Orphan Drug in Europe for LCA10; shares up 2% after hours https://seekingalpha.com/news/3297705-editas-meds-editminus-101-orphan-drug-in-europe-for-lca10-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3297705-editas-meds-editminus-101-orphan-drug-in-europe-for-lca10-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297703\" data-ts=\"1506457082\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTAS\" target=\"_blank\">CTAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297703-cintas-beats-0_15-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cintas beats by $0.15, beats on revenue</a></h4><ul><li>Cintas (NASDAQ:<a href='https://seekingalpha.com/symbol/CTAS' title='Cintas Corporation'>CTAS</a>): Q1 EPS of $1.45 <font color='green'>beats by $0.15</font>.</li><li>Revenue of $1.61B (+24.8% Y/Y) <font color='green'>beats by $40M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href='https://seekingalpha.com/pr/16951872-cintas-corporation-announces-fiscal-2018-first-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297703\" data-linked=\"Cintas beats by $0.15, beats on revenue\" data-tweet=\"$CTAS - Cintas beats by $0.15, beats on revenue https://seekingalpha.com/news/3297703-cintas-beats-0_15-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3297703-cintas-beats-0_15-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297701\" data-ts=\"1506457024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297701-nike-beats-0_09-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike beats by $0.09, misses on revenue</a></h4><ul><li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>): Q1 EPS of $0.57 <font color='green'>beats by $0.09</font>.</li><li>Revenue of $9.07B (+0.1% Y/Y) <font color='red'>misses by $20M</font>.</li><li>Shares <font color='green'>+2.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16951866-nike-inc-reports-fiscal-2018-first-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297701\" data-linked=\"Nike beats by $0.09, misses on revenue\" data-tweet=\"$NKE - Nike beats by $0.09, misses on revenue https://seekingalpha.com/news/3297701-nike-beats-0_09-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3297701-nike-beats-0_09-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297698\" data-ts=\"1506456784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297698-intra-cellular-launches-150m-stock-offering-shares-down-9-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular launches $150M stock offering; shares down 9% after hours</a></h4><ul><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>) <a href=\"https://seekingalpha.com/pr/16951833-intra-cellular-therapies-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences</a> a $150M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>9%</font>&nbsp;after hours. Today's close was $19.23.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297698\" data-linked=\"Intra-Cellular launches $150M stock offering; shares down 9% after hours\" data-tweet=\"$ITCI - Intra-Cellular launches $150M stock offering; shares down 9% after hours https://seekingalpha.com/news/3297698-intra-cellular-launches-150m-stock-offering-shares-down-9-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3297698-intra-cellular-launches-150m-stock-offering-shares-down-9-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297695\" data-ts=\"1506456489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297695-twilio-drops-after-amazon-announces-aws-two-way-texting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio drops after Amazon announces AWS two-way texting</a></h4><ul><li>        Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) closed today&nbsp;<font color='red'>down 6.62%&nbsp;</font>after Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) announces two-way text messaging feature in AWS.</li><li>               In a <a href=\"https://aws.amazon.com/blogs/aws/aws-pinpoint-launches-two-way-text-messaging/\" target=\"_blank\">blog post</a>, Amazon says Amazon Pinpoint launched the messaging feature last week that allows users to programmatically respond to end-user text messages.&nbsp;</li><li>                  Twilio had previously partnered with Amazon on text messaging services. &nbsp;   &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3297695\" data-linked=\"Twilio drops after Amazon announces AWS two-way texting\" data-tweet=\"$TWLO $TWLO $AMZN - Twilio drops after Amazon announces AWS two-way texting https://seekingalpha.com/news/3297695-twilio-drops-after-amazon-announces-aws-two-way-texting?source=tweet\" data-url=\"https://seekingalpha.com/news/3297695-twilio-drops-after-amazon-announces-aws-two-way-texting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297691\" data-ts=\"1506456090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297691-micron-technology-beats-0_18-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology beats by $0.18, beats on revenue</a></h4><ul><li>Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>): Q4 EPS of $2.02 <font color='green'>beats by $0.18</font>.</li><li>Revenue of $6.14B (+90.7% Y/Y) <font color='green'>beats by $180M</font>.</li><li>Shares <font color='green'>+3.7%</font>.</li><li><a href='https://seekingalpha.com/pr/16951821-micron-technology-inc-reports-results-fourth-quarter-full-year-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297691\" data-linked=\"Micron Technology beats by $0.18, beats on revenue\" data-tweet=\"$MU - Micron Technology beats by $0.18, beats on revenue https://seekingalpha.com/news/3297691-micron-technology-beats-0_18-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3297691-micron-technology-beats-0_18-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>112&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297688\" data-ts=\"1506455777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNA\" target=\"_blank\">CDNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297688-caredx-up-25-on-medicare-reimbursement-for-allosure-on-par-allomap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CareDx up 25% on Medicare reimbursement for AlloSure on par with AlloMap</a></h4><ul><li>CareDx (<a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+25.2%</font>) is up on a 10x surge in volume on the <a href=\"https://seekingalpha.com/pr/16950902-moldx-sets-allosure-reimbursement-2017-allomap-level\" target=\"_blank\">news </a>that Medicare reimbursement for AlloSure will be $2,840.75, the same as AlloMap. Coverage will start on October 9 for kidney transplant patients.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297688\" data-linked=\"CareDx up 25% on Medicare reimbursement for AlloSure on par with AlloMap\" data-tweet=\"$CDNA - CareDx up 25% on Medicare reimbursement for AlloSure on par with AlloMap https://seekingalpha.com/news/3297688-caredx-up-25-on-medicare-reimbursement-for-allosure-on-par-allomap?source=tweet\" data-url=\"https://seekingalpha.com/news/3297688-caredx-up-25-on-medicare-reimbursement-for-allosure-on-par-allomap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297686\" data-ts=\"1506455123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297686-abc-newscast-ends-year-no-1-for-first-time-in-21-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ABC newscast ends year at No. 1 for first time in 21 years</a></h4><ul>   <li>ABC's <i>World News Tonight</i> (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-0.8%</font>) has closed out the outgoing TV season <a href=\"http://www.seattletimes.com/business/abcs-world-news-breaks-a-21-year-streak/\" target=\"_blank\">hanging on to its No. 1 slot</a> among evening newscasts, finishing first for the first time in 21 years.</li>    <li>The program, anchored now by David Muir, averaged 8.25M viewers, ahead of 8.17M for <i>NBC Nightly News</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) and 6.56M for the <i>CBS Evening News</i> (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='red'>-3.1%</font>).</li>    <li>The last time ABC finished in first for the season, it was anchored by Peter Jennings. CBS is in transition with interim anchor Anthony Mason.</li>    <li>While evening newscasts aren't growing anymore, they are still in a flagship daypart reaching a collective 23M viewers per weeknight.</li>    <li>NBC, meanwhile, lauded its victory in the 25-54 age demographic.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297686\" data-linked=\"ABC newscast ends year at No. 1 for first time in 21 years\" data-tweet=\"$CMCSA $CMCSA $DIS - ABC newscast ends year at No. 1 for first time in 21 years https://seekingalpha.com/news/3297686-abc-newscast-ends-year-no-1-for-first-time-in-21-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3297686-abc-newscast-ends-year-no-1-for-first-time-in-21-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297685\" data-ts=\"1506454909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDRAF\" target=\"_blank\">BDRAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297685-bombardier-skies-much-14-ahead-of-u-s-trade-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bombardier skies as much as 14% ahead of U.S. trade ruling</a></h4><ul>     <li>Bombardier (<a href='https://seekingalpha.com/symbol/BDRAF' title='Bombardier Inc.A'>OTCQX:BDRAF</a>, <a href='https://seekingalpha.com/symbol/BDRBF' title='Bombardier Inc.B'>OTCQX:BDRBF</a>) <a href=\"http://www.reuters.com/article/bombardier-stocks/bombardier-shares-leap-14-percent-ahead-of-u-s-trade-court-ruling-idUSKCN1C12RH?il=0\" target=\"_blank\">surges as much as 14%</a> ahead of a preliminary ruling by the U.S. Commerce Department on Boeing&rsquo;s (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='red'>-0.1%</font>) complaint that the Canadian planemaker has been selling its CSeries jets in the U.S. at &ldquo;absurdly low&rdquo; prices while benefiting from unfair government subsidies.</li>     <li>Reuters reports Bombardier is <a href=\"https://seekingalpha.com/news/3297550-bombardier-aims-close-china-deals-soon\" target=\"_blank\">seeking to close deals with Chinese airlines</a> and is in talks with the country&rsquo;s three biggest airlines.</li>     <li>Quebec Finance Minister Leitao is <a href=\"https://www.bloomberg.com/news/articles/2017-09-26/quebec-attacks-boeing-for-predatory-trade-claim-on-bombardier\" target=\"_blank\">lashing out</a> at Boeing as \"behaving in a predatory way... clearly trying to drive Bombardier out of business.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297685\" data-linked=\"Bombardier skies as much as 14% ahead of U.S. trade ruling\" data-tweet=\"$BDRAF $BDRAF $BDRBF - Bombardier skies as much as 14% ahead of U.S. trade ruling https://seekingalpha.com/news/3297685-bombardier-skies-much-14-ahead-of-u-s-trade-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3297685-bombardier-skies-much-14-ahead-of-u-s-trade-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297671\" data-ts=\"1506452127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297671-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/ACTA' title='Actua Corporation'>ACTA</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RESN' title='Resonant'>RESN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/BSTI' title='Best, Inc.'>BSTI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297671\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$IZEA $ACTA $VNET - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3297671-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297671-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297662\" data-ts=\"1506449029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297662-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MCEP' title='Mid-Con Energy Partners'>MCEP</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/REXX' title='Rex Energy Corporation'>REXX</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/INT' title='World Fuel Services Corporation'>INT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SVM' title='Silvercorp Metals Inc.'>SVM</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297662\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$NDRO-OLD $MCEP $WTI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3297662-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297662-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297659\" data-ts=\"1506447931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELF\" target=\"_blank\">ELF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297659-spike-for-e-l-f-beauty-after-report-of-walgreens-store-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spike for e.l.f. Beauty after report of Walgreens store deal</a></h4><ul><li>Jefferies tips that e.l.f. Beauty Products (<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty'>ELF</a> <font color='green'>+6.2%</font>) were spotted on shelves at Walgreens stores. The firm suggests a store deal has been struck.</li><li>The Walgreens development appears to have sent e.l.f. shares flying.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297659\" data-linked=\"Spike for e.l.f. Beauty after report of Walgreens store deal\" data-tweet=\"$ELF - Spike for e.l.f. Beauty after report of Walgreens store deal https://seekingalpha.com/news/3297659-spike-for-e-l-f-beauty-after-report-of-walgreens-store-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3297659-spike-for-e-l-f-beauty-after-report-of-walgreens-store-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297658\" data-ts=\"1506447650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297658-andy-halls-exit-may-rung-bell-for-oil-bear-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Andy Hall&#39;s exit may have rung a bell for oil bear market</a></h4><ul><li>No asset class has truly bottomed until its leading bulls throw in the towel, and the case of oil might just be another example.</li><li>When longtime bull Andy Hall a few weeks back returned money to clients, he offered up another prediction - that his conversion to bear <a href=\"https://www.bloomberg.com/news/articles/2017-09-26/oil-god-s-final-prophecy-comes-true-as-crude-rallies-after-exit?cmpid=socialflow-twitter-business&amp;utm_content=business&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_medium=social\" target=\"_blank\">might just be a</a> great buy signal.</li><li>So far, he's been proven right. Struggling in the mid-$40s when Hall closed shop at the end of August, WTI crude has risen about 15% since. Brent crude has jumped to a two-year high of about $59 per barrel.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285380-another-oil-bull-bites-dust\" target=\"_blank\">Another oil bull bites the dust?</a> (Aug. 3)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/UHN' title='The United States Diesel-Heating Oil ETF, LP'>UHN</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297658\" data-linked=\"Andy Hall&#39;s exit may have rung a bell for oil bear market\" data-tweet=\"$USO $OIL $UWT - Andy Hall&#39;s exit may have rung a bell for oil bear market https://seekingalpha.com/news/3297658-andy-halls-exit-may-rung-bell-for-oil-bear-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3297658-andy-halls-exit-may-rung-bell-for-oil-bear-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297655\" data-ts=\"1506445808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IVTY\" target=\"_blank\">IVTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297655-invuity-launches-photonblade-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Invuity launches PhotonBlade; shares ahead 8%</a></h4><ul><li>Thinly traded micro cap Invuity (<a href='https://seekingalpha.com/symbol/IVTY' title='Invuity'>IVTY</a> <font color='green'>+7.7%</font>) is up on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16950138-invuity-announces-full-commercial-launch-photonblade\" target=\"_blank\">announcement </a>that the full commercial launch of PhotonBlade is underway. The company says the current model includes enhancements that improve energy delivery and optimize illumination performance.</li><li><a href=\"http://invuity.com/products/photonblade/\" target=\"_blank\">PhotonBlade </a>is a surgical instrument consisting of a proprietary insulated blade for the precise cutting and coagulation of tissue and illumination technology that does not require a separate generator.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297655\" data-linked=\"Invuity launches PhotonBlade; shares ahead 8%\" data-tweet=\"$IVTY - Invuity launches PhotonBlade; shares ahead 8% https://seekingalpha.com/news/3297655-invuity-launches-photonblade-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3297655-invuity-launches-photonblade-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297656\" data-ts=\"1506445596\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297656-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+10%</font>.BWINB <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CSGP' title='CoStar Group, Inc.'>CSGP</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297656\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$GHL $PN $PTVCB - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3297656-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297656-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297651\" data-ts=\"1506444848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297651-gold-slides-under-1300-yellen-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold slides under $1,300 as Yellen talks</a></h4><ul><li>Currently speaking, <a href=\"https://seekingalpha.com/news/3297648-yellen-giving-sides-reason-cheer\" target=\"_blank\">Janet Yellen has lines buffeting</a> both the doves and the hawks, but gold investors continue to bail. The yellow metal has added to the day's losses, now<font color='red'> off 1%</font>&nbsp;to $1,298 per ounce.</li><li>Earlier this month, gold was topping $1,350.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='ETFS Physical Swiss Gold Trust ETF'>SGOL</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/DGL' title='PowerShares DB Gold ETF'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/GHS' title='REX Gold Hedged S&P 500 ETF'>GHS</a>, <a href='https://seekingalpha.com/symbol/GHE' title='REX Gold Hedged FTSE Emerging Markets ETF'>GHE</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297651\" data-linked=\"Gold slides under $1,300 as Yellen talks\" data-tweet=\"$GLD $IAU $PHYS - Gold slides under $1,300 as Yellen talks https://seekingalpha.com/news/3297651-gold-slides-under-1300-yellen-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3297651-gold-slides-under-1300-yellen-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297650\" data-ts=\"1506444603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297650-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/ACTA' title='Actua Corporation'>ACTA</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/VRML' title='Vermillion, Inc.'>VRML</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-72%</font>. <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='red'>-71%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/RGEN' title='Repligen Corporation'>RGEN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CSSE' title='Chicken Soup for the Soul Entertainment, Inc. Cl A'>CSSE</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297650\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$IZEA $CDNA $ACTA - Midday Gainers / Losers https://seekingalpha.com/news/3297650-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3297650-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297646\" data-ts=\"1506444257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297646-dish-network-and-citadel-settle-long-retransmission-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish Network and Citadel settle long retransmission dispute</a></h4><ul>   <li>After a <a href=\"https://seekingalpha.com/news/3293935-dish-citadel-set-another-extension-talks-wlne\" target=\"_blank\">number of extensions</a>, Dish Network (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color='red'>-2.3%</font>) and Citadel Communications have <a href=\"http://www.broadcastingcable.com/news/currency/dish-citadel-reach-agreement-providence-retrans-dispute/168904\" target=\"_blank\">ended a long-running retransmission dispute</a> to bring WLNE-TV back to Dish's system.</li>    <li>The previous deal had expired Aug. 18, but the Providence, R.I., station didn't go dark, through a number of short extensions.</li>    <li>Dish had handed out digital antennas in case customers needed them to watch the ABC affiliate over the air.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297646\" data-linked=\"Dish Network and Citadel settle long retransmission dispute\" data-tweet=\"$DISH - Dish Network and Citadel settle long retransmission dispute https://seekingalpha.com/news/3297646-dish-network-and-citadel-settle-long-retransmission-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3297646-dish-network-and-citadel-settle-long-retransmission-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297638\" data-ts=\"1506442541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUCRF\" target=\"_blank\">LUCRF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297638-lucara-fetches-53m-in-sale-of-worlds-largest-uncut-diamond\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lucara fetches $53M in sale of world&#39;s largest uncut diamond</a></h4><ul>     <li>Lucara Diamond (<a href='https://seekingalpha.com/symbol/LUCRF' title='Lucara Diamond Corp.'>OTCPK:LUCRF</a> <font color='green'>+6.5%</font>) enjoys strong gains after <a href=\"http://www.reuters.com/article/us-lucara-diamond-sale/canadas-lucara-sells-worlds-largest-uncut-diamond-for-53-million-idUSKCN1C032G\" target=\"_blank\">selling the world's largest uncut diamond</a> for $53M, although the figure is <a href=\"http://business.financialpost.com/commodities/mining/biggest-gem-found-in-a-century-finally-sells-for-53-million-1\" target=\"_blank\">below the record $63M fetched previously</a> for another stone Lucara found at the same time.</li>     <li>The 1,109-carat stone was bought by British diamond dealer Graff Diamonds for $47,777/carat, an &ldquo;improvement&rdquo; on the highest bid received for the diamond at a Sotheby&rsquo;s auction in June 2016, says Lucara CEO and President William Lamb says.</li>     <li>Lucara, known for producing some of the world&rsquo;s biggest and best stones, unearthed the diamond at its Karowe mine in Botswana.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297638\" data-linked=\"Lucara fetches $53M in sale of world&#39;s largest uncut diamond\" data-tweet=\"$LUCRF - Lucara fetches $53M in sale of world&#39;s largest uncut diamond https://seekingalpha.com/news/3297638-lucara-fetches-53m-in-sale-of-worlds-largest-uncut-diamond?source=tweet\" data-url=\"https://seekingalpha.com/news/3297638-lucara-fetches-53m-in-sale-of-worlds-largest-uncut-diamond\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297635\" data-ts=\"1506441699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297635-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> LTEA <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SAM' title='Boston Beer Co.'>SAM</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/STLY' title='HG Holdings Inc'>STLY</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297635\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$LBCC $SAM $STLY - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3297635-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297635-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297630\" data-ts=\"1506441246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEI\" target=\"_blank\">PEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297630-preits-4-gain-leads-mall-names-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PREIT&#39;s 4% gain leads mall names higher</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16950655-preit-raises-180-million-september\" target=\"_blank\">The company closed on the sale </a>of its interest in the 801 Market Street office condo, with net proceeds of $30.75M. Earlier this month was the sale of Logan Valley Mall for proceeds of $33.2M, There was also a $120M preferred share series D issue this month, with funds used to redeem series A preferred, saving $1.58M annually in dividends.</li><li>Other transactions are in negotiation and expected to be completed in coming months, raising another $250M. <a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a>&nbsp;<font color='green'>+4%</font></li><li>Meanwhile, JPMorgan advises rotating out the hot industrial REIT sector and into retail REITs, malls in particular. The team upgrades Macerich (<a href='https://seekingalpha.com/symbol/MAC' title='Macerich Co.'>MAC</a> <font color='green'>+4.3%</font>), GGP (GGP <font color='green'>+2.8%</font>), and Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='green'>+3.3%</font>) to Overweight from Neutral. Alongside, they downgrade Taubman (<a href='https://seekingalpha.com/symbol/TCO' title='Taubman Centers, Inc.'>TCO</a> <font color='green'>+3%</font>) to Neutral from Overweight.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3297630\" data-linked=\"PREIT&#39;s 4% gain leads mall names higher\" data-tweet=\"$PEI $PEI $MAC - PREIT&#39;s 4% gain leads mall names higher https://seekingalpha.com/news/3297630-preits-4-gain-leads-mall-names-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3297630-preits-4-gain-leads-mall-names-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297628\" data-ts=\"1506440767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNIT\" target=\"_blank\">UNIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297628-uniti-groupminus-7_9-citi-cuts-to-neutral-on-windstream-woes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uniti Group -7.9% as Citi cuts to Neutral on Windstream woes</a></h4><ul>   <li>Uniti Group (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>) has <font color='red'>tumbled 7.9% </font>as lingering concerns at former parent Windstream (<a href=\"http://seekingalpha.com/symbol/WIN\" target=\"_blank\">WIN</a> <font color='red'>-7.1%</font>) have led Citigroup to downgrade Uniti to Neutral.</li>    <li>Windstream today is facing a notice of default from a large bondholder (surely Aurelius) tied to its spin-off of Communications Sales &amp; Leasing (now Uniti), and its already widening bond spreads might \"fuel further near-term underperformance for Uniti,\" says analyst Michael Rollins. (h/t Bloomberg)</li>    <li>The market looks like it's anticipating a cut in Windstream's lease payments, he says.</li>    <li>He's cut his price target on <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> to $18 from $27; shares today have fallen to $15.99, implying 12.6% upside from here.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297620-windstream-minus-5_6-percent-noteholder-claims-default-spin-deal\" target=\"_blank\">Windstream -5.6% after noteholder claims default in spin-off deal</a> (Sep. 26 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297628\" data-linked=\"Uniti Group -7.9% as Citi cuts to Neutral on Windstream woes\" data-tweet=\"$UNIT $UNIT $WINMQ - Uniti Group -7.9% as Citi cuts to Neutral on Windstream woes https://seekingalpha.com/news/3297628-uniti-groupminus-7_9-citi-cuts-to-neutral-on-windstream-woes?source=tweet\" data-url=\"https://seekingalpha.com/news/3297628-uniti-groupminus-7_9-citi-cuts-to-neutral-on-windstream-woes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297624\" data-ts=\"1506440293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCSC\" target=\"_blank\">FCSC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297624-fibrocells-fcxminus-007-shows-positive-initial-effect-in-early-stage-study-shares-down-7-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fibrocell&#39;s FCX-007 shows positive initial effect in early-stage study, shares down 7% on sustainability of treatment benefit</a></h4><ul><li>Thinly traded nano cap Fibrocell Science (<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a> <font color='red'>-7.4%</font>) slumps on almost a 7x surge in volume, albeit on turnover of only 373K shares, in apparent response to the company's <a href=\"https://seekingalpha.com/pr/16950828-fibrocell-reports-interim-results-phase-1-2-clinical-trial-fcxminus-007-gene-therapy\" target=\"_blank\">announcement </a>of preliminary data from its Phase 1/2 clinical trial assessing FCX-007 in patients with <a href=\"https://ghr.nlm.nih.gov/condition/dystrophic-epidermolysis-bullosa\" target=\"_blank\">recessive dystrophic epidermolysis bullosa</a> &#40;RDEB&#41;, an inherited disorder characterized by fragile skin that blisters easily.</li><li>The company announced results from three patients who received a single intradermal injection session of FCX-007 in the margins and across targeted wounds in addition to separate intact skin sites.</li><li>Four weeks after treatment, all (n=5/5) wounds were 75% healed. At week 12, 80% (n=4/5) of the wounds were 70% healed, implying that the treatment effect may not be durable.</li><li>FCX-007 was well-tolerated with no serious adverse events and no treatment-related adverse events reported.</li><li>After reviewing the results, the independent Data Safety Monitoring Board recommended the study continue as planned.</li><li>Investigators now intend to increase expression and dosing.</li><li>Fibrocell is developing FCX-007 in collaboration with Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='red'>-0.2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3297624\" data-linked=\"Fibrocell&#39;s FCX-007 shows positive initial effect in early-stage study, shares down 7% on sustainability of treatment benefit\" data-tweet=\"$FCSC $FCSC $XON - Fibrocell&#39;s FCX-007 shows positive initial effect in early-stage study, shares down 7% on sustainability of treatment benefit https://seekingalpha.com/news/3297624-fibrocells-fcxminus-007-shows-positive-initial-effect-in-early-stage-study-shares-down-7-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3297624-fibrocells-fcxminus-007-shows-positive-initial-effect-in-early-stage-study-shares-down-7-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297626\" data-ts=\"1506440122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297626-himax-disposes-of-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Himax disposes of investment</a></h4><ul><li>        Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) <a href=\"https://seekingalpha.com/pr/16950498-himax-technologies-announces-disposal-investment\" target=\"_blank\">announces</a> the disposal of an investment in a China-based provider of display driver IC backend processing.</li><li>               The disposal totals $32M in proceeds with a pre-tax gain of about $23.04M. The after-tax gain is estimated at $20.74M, contributing 12 cents GAAP net income per diluted ADS. &nbsp;&nbsp;</li><li>               Himax&rsquo;s initial investment of $8.96M represented a 14.46% stake. The company disposes of the investment due to diminishing value.&nbsp;</li><li>                  The sale will close no later than the end of Q4. &nbsp;   </li><li>               Himax shares are&nbsp;<font color='green'>up 1%</font>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297548-nomura-instinet-raises-himax-price-target\" target=\"_blank\">Nomura Instinet raises himax price target</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297626\" data-linked=\"Himax disposes of investment\" data-tweet=\"$HIMX - Himax disposes of investment https://seekingalpha.com/news/3297626-himax-disposes-of-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3297626-himax-disposes-of-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297625\" data-ts=\"1506439907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QEP\" target=\"_blank\">QEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297625-qeps-lower-guidance-removes-final-headwind-in-path-to-recovery-stifel-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QEP&#39;s lower guidance removes final headwind in path to recovery, Stifel says</a></h4><ul>     <li>QEP&nbsp;Resources (<a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a> <font color='red'>-9%</font>) plunges ~9% after <a href=\"https://seekingalpha.com/news/3297459-qep-resources-minus-9-percent-cutting-full-year-production-outlook\" target=\"_blank\">cutting its 2017 production outlook</a> following larger than expected declines from some pilot wells.</li>     <li>Stifel analysts view the news as negative and cut their stock price target to $23 from $26 but believe the bottom is near, as QEP's reduced guidance removes the final headwind in the stock's path to recovery following Monday's update.</li><li>Stifel believes valuations for QEP and many of its peers will attract M&amp;A and activism, and expects an active proxy season next spring as investors take a more active role in portfolio management if valuations remain depressed.</li><li>Source:&nbsp;Briefing.com</li></ul><div class=\"tiny-share-widget\" data-id=\"3297625\" data-linked=\"QEP&#39;s lower guidance removes final headwind in path to recovery, Stifel says\" data-tweet=\"$QEP - QEP&#39;s lower guidance removes final headwind in path to recovery, Stifel says https://seekingalpha.com/news/3297625-qeps-lower-guidance-removes-final-headwind-in-path-to-recovery-stifel-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3297625-qeps-lower-guidance-removes-final-headwind-in-path-to-recovery-stifel-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297622\" data-ts=\"1506439128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHAK\" target=\"_blank\">SHAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297622-wedbush-cools-on-shake-shack\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush cools on Shake Shack</a></h4><ul><li>Wedbush downgrades Shake Shack (<a href='https://seekingalpha.com/symbol/SHAK' title='Shake Shack'>SHAK</a> <font color='red'>-6.3%</font>) on mounting concerns over the impact of cannibalization on same-store sales growth and the advent of new food delivery services.</li><li>The restaurant chain is also seen facing high single-digit labor inflation.</li><li>Wedbush <a href=\"https://www.cnbc.com/2017/09/26/early-movers-shak-dri-jpm-fds-nwl-rht-asna-more.html\" target=\"_blank\">cuts</a> Shake Shack to Neutral and sets a price target of $36.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297622\" data-linked=\"Wedbush cools on Shake Shack\" data-tweet=\"$SHAK - Wedbush cools on Shake Shack https://seekingalpha.com/news/3297622-wedbush-cools-on-shake-shack?source=tweet\" data-url=\"https://seekingalpha.com/news/3297622-wedbush-cools-on-shake-shack\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297620\" data-ts=\"1506438882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIN\" target=\"_blank\">WIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297620-windstreamminus-5_6-after-noteholder-claims-default-in-spin-off-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Windstream -5.6% after noteholder claims default in spin-off deal</a></h4><ul>   <li>Windstream Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) is <font color='red'>off 5.6%</font> after receiving a notice of default from a large noteholder over transactions around the spin-off of its REIT unit Communications Sales &amp; Leasing.</li>    <li>The notice -- from a holder claiming more than 25% of the 6.375% senior notes due 2023 (Bloomberg says that's Aurelius Capital Management) -- alleges that asset transfers and associated leases in April 2015 were essentially a sale-and-leaseback transaction.</li>    <li>That doesn't comply with the covenants covering sale and leaseback, the noteholder says.</li><li>Windstream denies that the transactions are a sale-leaseback.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297620\" data-linked=\"Windstream -5.6% after noteholder claims default in spin-off deal\" data-tweet=\"$WIN $WINMQ - Windstream -5.6% after noteholder claims default in spin-off deal https://seekingalpha.com/news/3297620-windstreamminus-5_6-after-noteholder-claims-default-in-spin-off-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3297620-windstreamminus-5_6-after-noteholder-claims-default-in-spin-off-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297586\" data-ts=\"1506438045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297586-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/VRML' title='Vermillion, Inc.'>VRML</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AMPH' title='Amphastar'>AMPH</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-73%</font>. <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='red'>-67%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297586\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$MBRX $VRML $AMPH - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3297586-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3297586-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297612\" data-ts=\"1506437639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297612-fabrinetplus-2_6-sets-forth-new-ceo-exec-chairman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fabrinet +2.6% as it sets forth with new CEO, exec chairman</a></h4><ul>   <li>Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) is <font color='green'>up 2.6%</font> in first morning action after naming Seamus Grady its <a href=\"https://seekingalpha.com/pr/16950181-fabrinet-names-seamus-grady-chief-executive-officer\" target=\"_blank\">new chief executive</a>.</li>    <li>Grady will join the board as well, and initially report to Tom Mitchell, who's been named executive chairman of the company.</li>    <li>Most recently, Grady was executive VP and chief operating officer of Sanmina's Mechanical Systems Division. He spent 13 years at that company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297612\" data-linked=\"Fabrinet +2.6% as it sets forth with new CEO, exec chairman\" data-tweet=\"$FN - Fabrinet +2.6% as it sets forth with new CEO, exec chairman https://seekingalpha.com/news/3297612-fabrinetplus-2_6-sets-forth-new-ceo-exec-chairman?source=tweet\" data-url=\"https://seekingalpha.com/news/3297612-fabrinetplus-2_6-sets-forth-new-ceo-exec-chairman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297602\" data-ts=\"1506436014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297602-catalyst-bios-next-gen-factor-ix-variant-orphan-drug-in-u-s-for-hemophilia-b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio&#39;s next-gen Factor IX variant an Orphan Drug in U.S. for hemophilia B</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16950812-catalyst-biosciences-granted-fda-orphan-drug-designation-subcutaneous-recombinant-human\" target=\"_blank\">designates </a>Catalyst Biosciences' (<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-6.5%</font>) CB 2679d/ISU304, a subcutaneous next-generation recombinant human Factor IX variant, an Orphan Drug for the treatment of hemophilia B. It also has Orphan Drug status in Europe.</li><li>The candidate is currently being evaluated in a Phase 1/2 proof-of-concept study with topline data expected by year-end.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.</li><li>Shares are down in apparent \"sell on the news\" action after a&nbsp;<font color='green'>63%</font>&nbsp;runup since mid-August.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297602\" data-linked=\"Catalyst Bio&#39;s next-gen Factor IX variant an Orphan Drug in U.S. for hemophilia B\" data-tweet=\"$CBIO - Catalyst Bio&#39;s next-gen Factor IX variant an Orphan Drug in U.S. for hemophilia B https://seekingalpha.com/news/3297602-catalyst-bios-next-gen-factor-ix-variant-orphan-drug-in-u-s-for-hemophilia-b?source=tweet\" data-url=\"https://seekingalpha.com/news/3297602-catalyst-bios-next-gen-factor-ix-variant-orphan-drug-in-u-s-for-hemophilia-b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297601\" data-ts=\"1506435744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDS\" target=\"_blank\">FDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297601-factsetplus-3_9-q4-beats-on-solid-revenue-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FactSet +3.9% as Q4 beats on solid revenue growth</a></h4><ul>   <li>FactSet Research Systems (NYSE:<a href='https://seekingalpha.com/symbol/FDS' title='FactSet Research Systems Inc.'>FDS</a>) is <font color='green'>up 3.9%</font> after beating on top and bottom lines with its <a href=\"https://seekingalpha.com/news/3297511-factset-research-systems-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li>    <li>Revenues grew 13.7% while organic revenues were up 6.3% to $301.3M.</li>    <li>Annual Subscription Value, meanwhile, rose to $1.32B from $1.15B, and organic ASV rose 5.7%. ASV from U.S. operations rose 9.4% to $825.1M.</li>    <li>Buy-side ASV growth was 5.9%, while sell-side ASV growth came to 4.6%. Buy-side clients made up 84% of ASV.</li>    <li>Client count was 4,744 (up 115 clients over three months); user count was 88,846 (up 2,821 users in three months).</li>    <li>Quarterly free cash flow was $89.3M, vs. a year-ago $57M.</li>    <li>For fiscal 2018's Q1, it's guiding to GAAP revenues of $327M-$333M (vs. consensus for $328.2M), an adjusted operating margin of 31-32%, annual effective tax rate of 25-26%, and adjusted EPS of $1.93-$1.99 (12% growth at the midpoint, and vs. consensus for $1.94).</li>    <li><a href=\"http://investor.factset.com/investors/audiocasts\" target=\"_blank\">Conference call</a> to come at 11 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16950578-factset-reports-solid-revenue-earnings-growth-fourth-quarter-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3297601\" data-linked=\"FactSet +3.9% as Q4 beats on solid revenue growth\" data-tweet=\"$FDS - FactSet +3.9% as Q4 beats on solid revenue growth https://seekingalpha.com/news/3297601-factsetplus-3_9-q4-beats-on-solid-revenue-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3297601-factsetplus-3_9-q4-beats-on-solid-revenue-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297600\" data-ts=\"1506435588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297600-fda-oks-lannetts-generic-focalin-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Lannett&#39;s generic Focalin; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16950553-lannett-receives-approval-dexmethylphenidate-hydrochloride-tablets-2_5-mg-5-mg-10-mg\" target=\"_blank\">approves </a>Lannett Company's (<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='green'>+1.2%</font>) Dexmethylphenidate Hydrochloride Tablets, 2.5 mg, 5 mg and 10 mg, the therapeutic equivalent to Novartis' ADHD med Focalin. Commercial launch will commence in the coming months.</li><li>Per IMS, the U.S. wholesale market is ~$34M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297600\" data-linked=\"FDA OKs Lannett&#39;s generic Focalin; shares up 1%\" data-tweet=\"$LCI - FDA OKs Lannett&#39;s generic Focalin; shares up 1% https://seekingalpha.com/news/3297600-fda-oks-lannetts-generic-focalin-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3297600-fda-oks-lannetts-generic-focalin-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297594\" data-ts=\"1506434917\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CF\" target=\"_blank\">CF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297594-fertilizer-makers-shares-face-top-in-urea-prices-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fertilizer makers\u2019 shares face top in urea prices, analyst says</a></h4><ul>     <li>Fertilizer shares could retreat as the run-up in urea prices shows signs of easing, with CF Industries (<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='red'>-3%</font>), Agrium (AGU <font color='red'>-0.7%</font>) and Potash Corp. (POT <font color='red'>-0.5%</font>) vulnerable following recent big gains, according to Cowen analyst Charles Neivert, citing anecdotal evidence from conversations with ag contacts.</li>     <li>Softer prices may come as U.S. farmers reconsider fall applications of nitrogen and Indian demand is suspect due to high prices; if that happens, international prices could retreat to $200-$215/metric ton by year-end.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297594\" data-linked=\"Fertilizer makers\u2019 shares face top in urea prices, analyst says\" data-tweet=\"$CF $CF $NTR - Fertilizer makers\u2019 shares face top in urea prices, analyst says https://seekingalpha.com/news/3297594-fertilizer-makers-shares-face-top-in-urea-prices-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3297594-fertilizer-makers-shares-face-top-in-urea-prices-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297591\" data-ts=\"1506434754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KDMN\" target=\"_blank\">KDMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297591-kadmon-prices-stock-offering-3-shares-down-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kadmon prices stock offering at $3; shares down 21%</a></h4><ul><li>Kadmon Holdings (<a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-20.8%</font>) <a href=\"https://seekingalpha.com/pr/16951210-kadmon-announces-pricing-public-offerings-common-stock-warrants\" target=\"_blank\">prices </a>its public offering of 9.6M shares of common stock at $3 per share and accompanying warrants. Gross proceeds should be $72M.</li><li>Underwriters over-allotment is an additional 2.775M shares and/or warrants to purchase up to 1.11M shares. Closing date is September 28.</li><li>Each warrant is exercisable for 0.40 of a share of common at $3.25.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297591\" data-linked=\"Kadmon prices stock offering at $3; shares down 21%\" data-tweet=\"$KDMN - Kadmon prices stock offering at $3; shares down 21% https://seekingalpha.com/news/3297591-kadmon-prices-stock-offering-3-shares-down-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3297591-kadmon-prices-stock-offering-3-shares-down-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297592\" data-ts=\"1506434691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARTW\" target=\"_blank\">ARTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297592-arts-way-on-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Art&#39;s-Way on the move</a></h4><ul><li>Art's-Way Manufacturing (NASDAQ:<a href='https://seekingalpha.com/symbol/ARTW' title='Art&#39;s-Way Manufacturing Co., Inc.'>ARTW</a>) seems to bought a two-day ticket to the amusement park, with shares taking a recent roller coaster ride.</li><li>After <font color='green'>rising over 15%</font> in yesterday's session, the stock is now <font color='red'>down about 10%</font> in early trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297592\" data-linked=\"Art&#39;s-Way on the move\" data-tweet=\"$ARTW - Art&#39;s-Way on the move https://seekingalpha.com/news/3297592-arts-way-on-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3297592-arts-way-on-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297585\" data-ts=\"1506434050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFO\" target=\"_blank\">INFO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297585-ihs-markit-down-4_5-after-q3-beats-guidance-straddle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IHS Markit down 4.5% after Q3 beats, guidance straddle</a></h4><ul><li>        IHS Markit (NASDAQ:<a href='https://seekingalpha.com/symbol/INFO' title='IHS Markit Ltd.'>INFO</a>) shares are&nbsp;<font color='red'>down 4.49%&nbsp;</font>despite beating Q3 estimates this morning and straddling FY17 consensus.</li><li>               FY17 outlook: revenue, $3.49B to $3.56B (consensus:$3.55B); Adjusted EBITDA, $1.375B to $1.4B; EPS, $2.02 to $2.08 (consensus: $2.06).&nbsp;</li><li>               Segment revenue: Resources, $202M (-4% Y/Y); Transportation, $257M (+13%); Consolidated Markets &amp; Solutions, $139M (+7%); Financial Services, $307M.&nbsp;</li><li>                  Segment adjusted EBITDA: Resources, $89M (-6%); Transportation, $110M (+24%); Consolidated Markets &amp; Solutions, $32M (-4%); Financial Services, $138M.    </li><li>               Cash: Cash flow from operations totaled $267M with FCF of $206M. The company ended the quarter with $153.8M in cash and equivalents.&nbsp;</li><li>               Acquisition: In a separate <a href=\"https://seekingalpha.com/pr/16950517-ihs-markit-announces-acquisition-automotivemastermind-inc-leader-predictive-analytics\" target=\"_blank\">press release</a>, the company announces acquiring the automotive predictive analytics company automotiveMastermind. IHS Markit will acquire about 78% of the company for $392M, which can increase to $435M depending on performance. &nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16950514-ihs-markit-reports-third-quarter-2017-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297493-ihs-markit-beats-0_04-beats-revenue\" target=\"_blank\">IHS Markit beats by $0.04, beats on revenue</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297585\" data-linked=\"IHS Markit down 4.5% after Q3 beats, guidance straddle\" data-tweet=\"$INFO - IHS Markit down 4.5% after Q3 beats, guidance straddle https://seekingalpha.com/news/3297585-ihs-markit-down-4_5-after-q3-beats-guidance-straddle?source=tweet\" data-url=\"https://seekingalpha.com/news/3297585-ihs-markit-down-4_5-after-q3-beats-guidance-straddle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297583\" data-ts=\"1506433600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGEN\" target=\"_blank\">RGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297583-repligen-continues-slide-ahead-of-investor-day-shares-down-11-in-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Repligen continues slide ahead of Investor Day; shares down 11% in a week</a></h4><ul><li>The selloff continues in Repligen (<a href='https://seekingalpha.com/symbol/RGEN' title='Repligen Corporation'>RGEN</a> <font color='red'>-7%</font>) ahead of Friday's <a href=\"https://seekingalpha.com/pr/16941969-repligen-announces-analyst-day-webcast\" target=\"_blank\">Investor and Analyst Day</a> in New York. Shares have lost ~11% since last week after running up 17% since mid-August.</li><li>The theme of the event is \"Bioprocessing Industry Trends and Growth Drivers.\"</li><li>The company recently closed its $359M takeover of privately held Spectrum, a specialist in filtration, purification and chromatography.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297583\" data-linked=\"Repligen continues slide ahead of Investor Day; shares down 11% in a week\" data-tweet=\"$RGEN - Repligen continues slide ahead of Investor Day; shares down 11% in a week https://seekingalpha.com/news/3297583-repligen-continues-slide-ahead-of-investor-day-shares-down-11-in-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3297583-repligen-continues-slide-ahead-of-investor-day-shares-down-11-in-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297582\" data-ts=\"1506433432\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297582-pareteumplus-23_6-enters-eastern-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +23.6% as it enters Eastern Europe</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color='green'>up 23.6%</font> out of today's open after word that it's <a href=\"https://www.pareteum.com/news/pareteum-enters-eastern-european-market-mobile-virtual-network-enabler-agreement-adding-24000000-revenue-backlog/\" target=\"_blank\">entering the market in Eastern Europe</a>.</li>    <li>The company's moving in with a five-year Mobile Virtual Network enabler agreement with a telecom there, which will provide the Pareteum Managed Services Platform.</li>    <li>That will allow the telecom to provide services to MVNOs in its market.</li>    <li>Initial onboarding of subscribers is expected to begin in Q2 2018, and the expansion of the customer opportunity is seen at 2M subscribers.</li>    <li>The move adds $24M to Pareteum's revenue backlog in the first three years, but the company expects the full five-year value of the contract to more than double that amount as enrollment accelerates and adds more monthly recurring revenues.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297582\" data-linked=\"Pareteum +23.6% as it enters Eastern Europe\" data-tweet=\"$TEUM - Pareteum +23.6% as it enters Eastern Europe https://seekingalpha.com/news/3297582-pareteumplus-23_6-enters-eastern-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3297582-pareteumplus-23_6-enters-eastern-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297581\" data-ts=\"1506432931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297581-morgan-stanley-talks-tesla-car-population-explosion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley talks Tesla car population explosion</a></h4><ul> <li>Morgan Stanley analyst Adam Jonas issues a forecast on the level of Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) vehicles on the road in the future.</li> <li>Jonas estimates the global on-road population of Tesla vehicles will reach nearly 300K units by the end of 2017 and 531K units by the end of 2018. Looking even further out, he sees a 10X car population explosion by 2023 from 2017 and calls out about 32M Tesla units on the road way out in 2040.</li> <li>Word-of-mouth advertising is seen aiding Tesla as the Model 3 becomes commonplace in neighborhoods.</li> <li>Morgan Stanley sets a base case price target on Tesla of $317. The bull case PT is $526 off of favorable valutaions for Gigafactories/Tesla Mobility/Tesla Energy and the bear case PT is $175 if Tesla remains a niche player.</li> <li>Telsa is <font color='green'>up 1.30%</font> to $349.32 in opening trades.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297581\" data-linked=\"Morgan Stanley talks Tesla car population explosion\" data-tweet=\"$TSLA - Morgan Stanley talks Tesla car population explosion https://seekingalpha.com/news/3297581-morgan-stanley-talks-tesla-car-population-explosion?source=tweet\" data-url=\"https://seekingalpha.com/news/3297581-morgan-stanley-talks-tesla-car-population-explosion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>118&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297575\" data-ts=\"1506432178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSBF\" target=\"_blank\">TOSBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297575-rival-bidder-wants-to-lure-apple-out-of-toshiba-chip-unit-winner\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rival bidder wants to lure Apple out of Toshiba chip unit winner</a></h4><ul><li>        Toshiba (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) selected a winning chip unit but nothing can go smoothly for that process so a rival consortium is trying to woo Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) from the leading bidder.</li><li>                  Toshiba told creditors that the Bain-backed winning consortium wasn&rsquo;t finalized yet because Apple hadn&rsquo;t agreed to all the terms.    </li><li>               <a href=\"https://www.bloomberg.com/news/articles/2017-09-25/kkr-said-to-be-wooing-apple-to-switch-sides-in-toshiba-bid\" target=\"_blank\">Bloomberg</a> reports that the KKR-backed consortium wants Apple to switch to its team, which also includes Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>).</li><li>                  Apple previously objected to Western Digital&rsquo;s participation, fearing the company would try to control the unit and create a power concentration in the chip market.    </li><li>               Western Digital has threatened to legally block the chip unit sale without its permission, which essentially means complicating a sale to any other consortium.&nbsp;</li><li>               Apple wants to get the best chip prices for itself and is reportedly negotiating supply terms with Toshiba before signing off on any deal.&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 0.8%</font>&nbsp;premarket.&nbsp;</li><li>               Western Digital shares are&nbsp;<font color='green'>up 1.03%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297285-reuters-toshiba-chip-unit-deal-delayed-apple\" target=\"_blank\">Reuters: Toshiba chip unit deal delayed by Apple</a> (Sept. 25)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297517-western-digital-comments-arbitrations-filed-toshiba\" target=\"_blank\">Western Digital comments on arbitrations filed against Toshiba</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297575\" data-linked=\"Rival bidder wants to lure Apple out of Toshiba chip unit winner\" data-tweet=\"$TOSBF $TOSBF $TOSYY - Rival bidder wants to lure Apple out of Toshiba chip unit winner https://seekingalpha.com/news/3297575-rival-bidder-wants-to-lure-apple-out-of-toshiba-chip-unit-winner?source=tweet\" data-url=\"https://seekingalpha.com/news/3297575-rival-bidder-wants-to-lure-apple-out-of-toshiba-chip-unit-winner\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297574\" data-ts=\"1506432135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297574-investors-shaken-ptcs-briefing-docs-ahead-of-ad-com-for-dmd-candidate-translarna-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors shaken by PTC&#39;s briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket</a></h4><ul><li>PTC Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a>) slumps&nbsp;<font color='red'>14%</font>&nbsp;premarket on increased volume in apparent response to the release of briefing documents ahead of Thursday's FDA Advisory Committee <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm573363.htm\" target=\"_blank\">review </a>of its marketing application for Duchenne muscular dystrophy &#40;DMD&#41; candidate Translarna (ataluren).</li><li>This a rare case of an advisory committee review of an application \"filed-over-protest\" in which the applicant insists that the FDA further review the data that was initially regarded as insufficient to support approval. On two prior occasions, 2011 and 2016, the FDA rejected the company's application under \"Refuse to File\" which means the filing was not complete enough to permit a substantive review.</li><li>The present situation is the result of the FDA's controversial approval of Sarepta Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) application for EXONDYS 51 in September 2016 that many observers perceived lacked sufficient proof that the drug works.</li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM577349.pdf\" target=\"_blank\">FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM577350.pdf\" target=\"_blank\">Addendum to FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM577351.pdf\" target=\"_blank\">Errata to FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM577352.pdf\" target=\"_blank\">PTC briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM577353.pdf\" target=\"_blank\">Addendum to PTC briefing doc&nbsp;</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297574\" data-linked=\"Investors shaken by PTC&#39;s briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket\" data-tweet=\"$PTCT $PTCT $SRPT - Investors shaken by PTC&#39;s briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket https://seekingalpha.com/news/3297574-investors-shaken-ptcs-briefing-docs-ahead-of-ad-com-for-dmd-candidate-translarna-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3297574-investors-shaken-ptcs-briefing-docs-ahead-of-ad-com-for-dmd-candidate-translarna-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297573\" data-ts=\"1506432104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297573-kohls-announces-ceo-succession-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kohl&#39;s announces CEO succession plan</a></h4><ul> <li>Kohl's (NYSE:<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a>) announces that CEO&nbsp;Kevin Mansell&nbsp;will retire in May of 2018 at the close       of the company&rsquo;s annual shareholders meeting.</li><li>Chief Merchandising Officer Michelle Gass will assume       the CEO role at that time.</li><li>Sona Chawla, Kohl&rsquo;s chief operating officer,       will assume the role of president.</li> <li>Source: <a href=\"https://seekingalpha.com/pr/16951025-kohl-s-announces-ceo-succession-plan-kevin-mansell-retire-may-2018-michelle-gass-appointed\" target=\"_blank\">Press Release</a></li><li>Shares of Kohl's are&nbsp;<font color='red'>down 0.45%</font>&nbsp;premarket to $46.00.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297573\" data-linked=\"Kohl&#39;s announces CEO succession plan\" data-tweet=\"$KSS - Kohl&#39;s announces CEO succession plan https://seekingalpha.com/news/3297573-kohls-announces-ceo-succession-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3297573-kohls-announces-ceo-succession-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297572\" data-ts=\"1506431999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297572-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+42%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+36%</font>&nbsp;on several high-profile <a href=\"https://seekingalpha.com/pr/16950764-izea-reports-seven-figure-contract-fortune-500-company\" target=\"_blank\">contract wins</a>.</li>     <li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+29%</font>&nbsp;on FDA <a href=\"https://seekingalpha.com/news/3297536-moleculin-announces-fda-approval-annamycin-ind-shares-ahead-28-percent-premarket\" target=\"_blank\">approval</a> of Annamycin IND.</li>     <li><a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+18%</font>&nbsp;on Q4 earnings <a href=\"https://seekingalpha.com/news/3297420-ascena-retail-group-beats-0_08-beats-revenue\" target=\"_blank\">beat</a>.</li>     <li><a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a> <font color='green'>+16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297544\" target=\"_blank\">announcing</a> leveraged recap.</li>     <li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/SNX' title='SYNNEX Corporation'>SNX</a> <font color='green'>+9%</font>&nbsp;on Q3 earning <a href=\"https://seekingalpha.com/news/3297426-synnex-beats-0_19-beats-revenue\" target=\"_blank\">result</a>.</li>     <li>ITUS <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='green'>+5%</font>&nbsp;on QR-010 <a href=\"https://seekingalpha.com/news/3297428-proqrs-cf-candidate-qrminus-010-shows-encouraging-action-early-stage-study-shares-10-percent\" target=\"_blank\">showing</a> encouraging action in early-stage study.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297572\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$TEUM $IZEA $MBRX - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3297572-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3297572-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297570\" data-ts=\"1506431826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297570-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>&nbsp;<font color='red'>-74%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297516-axovants-intepirdine-fails-beat-placebo-late-stage-alzheimers-study\" target=\"_blank\">announcing</a> negative topline results of Intepirdine Phase 3 MINDSET trial in Alzheimer''s disease.</li><li><a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>&nbsp;<font color='red'>-58%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297520-genocea-bails-genital-herpes-vaccine-shifts-cancer-vaccines-cuts-workforce-40-percent-shares\" target=\"_blank\">announcing</a> strategic shift to immuno-oncology and development of neoantigen cancer vaccines.</li><li><a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a>&nbsp;<font color='red'>-21%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297556-kadmon-readies-equity-offering-shares-22-percent-premarket\" target=\"_blank\">announcing</a> proposed public offering of common stock and warrants.</li><li><a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='red'>-14%</font>.</li><li><a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297459-qep-resources-minus-9-percent-cutting-full-year-production-outlook\" target=\"_blank\">lowering</a> FY 2017 production guidance.</li><li><a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297553-therapeuticsmd-prices-stock-offering-shares-9-percent-premarket\" target=\"_blank\">pricing</a> common stock offering.</li><li><a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297518-sabra-health-minus-6-percent-transitions-version-3_0-raises-capital\" target=\"_blank\">closing</a> the sale/leaseback of 21 of its 24 skilled nursing/transitional care facilities for $378M.</li><li><a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3297570\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$AXON-OLD $GNCA $KDMN - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3297570-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3297570-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297569\" data-ts=\"1506431815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297569-carnival-beats-0_09-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carnival beats by $0.09, beats on revenue</a></h4><ul><li>Carnival (NYSE:<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a>): Q3 EPS of $2.29 <font color='green'>beats by $0.09</font>.</li><li>Revenue of $5.52B (+8.2% Y/Y) <font color='green'>beats by $130M</font>.</li><li>Shares <font color='green'>+1.97%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/16951228-carnival-corporation-and-plc-reports-third-quarter-earnings\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297569\" data-linked=\"Carnival beats by $0.09, beats on revenue\" data-tweet=\"$CCL $CUK - Carnival beats by $0.09, beats on revenue https://seekingalpha.com/news/3297569-carnival-beats-0_09-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3297569-carnival-beats-0_09-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297566\" data-ts=\"1506431221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTK\" target=\"_blank\">FTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297566-flotek-guides-q3-revenues-lower-due-to-hurricane-impacts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flotek guides Q3 revenues lower due to hurricane impacts</a></h4><ul>     <li>Flotek Industries (NYSE:<a href='https://seekingalpha.com/symbol/FTK' title='Flotek Industries, Inc.'>FTK</a>) <font color='red'>-2.8%</font> premarket after estimating Q3 revenues will come in <a href=\"https://seekingalpha.com/pr/16950291-flotek-industries-inc-provides-update-third-quarter-expectations\" target=\"_blank\">~$5M less than previously expected</a>, with incremental costs rising by less than $1M, due to impacts from Hurricanes Harvey and Irma.</li>     <li>FTK says some of its chemical suppliers declared&nbsp;force majeure, which affected client  drilling and completion activity, and damages suffered by Florida citrus crops will affect availability and pricing of domestic citrus oil.</li>     <li>The company expects activity delays will be corrected in Q4.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297566\" data-linked=\"Flotek guides Q3 revenues lower due to hurricane impacts\" data-tweet=\"$FTK - Flotek guides Q3 revenues lower due to hurricane impacts https://seekingalpha.com/news/3297566-flotek-guides-q3-revenues-lower-due-to-hurricane-impacts?source=tweet\" data-url=\"https://seekingalpha.com/news/3297566-flotek-guides-q3-revenues-lower-due-to-hurricane-impacts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297558\" data-ts=\"1506431116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297558-biolinerx-initiates-phase-1b-2-trial-for-blminus-8040-in-aml-under-immunotherapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx initiates Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration</a></h4><ul><li>BioLineRx (NASDAQ:<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a>) <a href=\"https://seekingalpha.com/pr/16950584-biolinerx-announces-initiation-phase-1b-2-trial-blminus-8040-aml-immunotherapy-collaboration\" target=\"_blank\">initiates</a> a Phase 1b/2 trial, BATTLE, assessing the combination of <a href=\"http://www.biolinerx.com/default.asp?pageid=98\" target=\"_blank\">BL-8040</a>&nbsp;and&nbsp;<a href=\"https://www.gene.com/media/product-information/tecentriq\" target=\"_blank\">atezolizumab</a> (Roche's TECENTRIQ) for the maintenance treatment of patients with intermediate and high-risk acute myeloid leukemia who have achieved a complete response following induction and consolidation therapy.</li> <li>The trial will enroll up to 60 patients. The primary endpoint is relapse-free survival. The effect of the combination therapy on minimal residual disease, multiple immunological parameters and potential biomarkers will also be evaluated.</li>    <li><a href=\"http://www.biolinerx.com/default.asp?pageid=98&amp;itemid=41\" target=\"_blank\">BL-8040</a>&nbsp;is a short peptide for the treatment of acute myeloid leukemia, solid tumors and certain hematological indications. It functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;premarket on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3297558\" data-linked=\"BioLineRx initiates Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration\" data-tweet=\"$BLRX - BioLineRx initiates Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration https://seekingalpha.com/news/3297558-biolinerx-initiates-phase-1b-2-trial-for-blminus-8040-in-aml-under-immunotherapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3297558-biolinerx-initiates-phase-1b-2-trial-for-blminus-8040-in-aml-under-immunotherapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297560\" data-ts=\"1506430678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMPH\" target=\"_blank\">AMPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297560-fda-oks-amphastars-generic-version-of-bloxiverz-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Amphastar&#39;s generic version of Bloxiverz; shares up 3% premarket</a></h4><ul><li>Thinly traded small cap Amphastar Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AMPH' title='Amphastar'>AMPH</a>) is up&nbsp;<font color='green'>3%&nbsp;</font>premarket on light volume in response to the <a href=\"https://seekingalpha.com/pr/16950322-amphastar-announces-approval-neostigmine-methylsulfate-injection-usp\" target=\"_blank\">FDA's approval</a>&nbsp;of its Neostigmine Methylsulfate Injection, USP, 1 mg/mL, 10 mL and 0.5 mg/mL, 10 mL vial, a generic version of Avadel's <a href=\"http://www.pharmacytimes.com/publications/health-system-edition/2013/november2013/neostigmine-methylsulfate-injection-bloxiverz\" target=\"_blank\">Bloxiverz</a>, a reversal agent for neuromuscular blocking agents used in surgery.</li><li>The U.S. market is ~$185M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297560\" data-linked=\"FDA OKs Amphastar&#39;s generic version of Bloxiverz; shares up 3% premarket\" data-tweet=\"$AMPH - FDA OKs Amphastar&#39;s generic version of Bloxiverz; shares up 3% premarket https://seekingalpha.com/news/3297560-fda-oks-amphastars-generic-version-of-bloxiverz-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3297560-fda-oks-amphastars-generic-version-of-bloxiverz-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297556\" data-ts=\"1506430090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KDMN\" target=\"_blank\">KDMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297556-kadmon-readies-equity-offering-shares-down-22-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kadmon readies equity offering; shares down 22% premarket</a></h4><ul><li>Thinly traded micro cap Kadmon Holdings (NYSE:<a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a>) is down&nbsp;<font color='red'>22%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16950176-kadmon-announces-proposed-public-offering-common-stock-warrants\" target=\"_blank\">upcoming public offering</a> of common stock. Price, volume and terms have yet to be announced.</li><li>Net proceeds will fund pipeline development, R&amp;D, preclinical studies and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297556\" data-linked=\"Kadmon readies equity offering; shares down 22% premarket\" data-tweet=\"$KDMN - Kadmon readies equity offering; shares down 22% premarket https://seekingalpha.com/news/3297556-kadmon-readies-equity-offering-shares-down-22-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3297556-kadmon-readies-equity-offering-shares-down-22-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297553\" data-ts=\"1506429868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXMD\" target=\"_blank\">TXMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297553-therapeuticsmd-prices-stock-offering-shares-down-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TherapeuticsMD prices stock offering, shares down 9% premarket</a></h4><ul><li>TherapeuticsMD (NYSEMKT:<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a>) slips&nbsp;<font color='red'>9%</font>&nbsp;premarket on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16950364-therapeuticsmd-announces-pricing-common-stock-offering\" target=\"_blank\">public offering</a> of 12.4M shares of common stock at $5.65 per share. Closing date is September 28.</li><li>Yesterday's close was $6.06.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297553\" data-linked=\"TherapeuticsMD prices stock offering, shares down 9% premarket\" data-tweet=\"$TXMD - TherapeuticsMD prices stock offering, shares down 9% premarket https://seekingalpha.com/news/3297553-therapeuticsmd-prices-stock-offering-shares-down-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3297553-therapeuticsmd-prices-stock-offering-shares-down-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297548\" data-ts=\"1506429226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297548-nomura-instinet-raises-himax-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura Instinet raises himax price target</a></h4><ul><li>        Nomura Instinet <a href=\"https://www.streetinsider.com/Analyst+Comments/Himax+Technologies+%28HIMX%29+PT+Raised+to+%2412+at+NomuraInstinet%3B+New+3D+sensing+project+may+start+in+1H18/13327754.html\" target=\"_blank\">raises</a> its price target on Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) by $2 to $12 and maintains a Buy rating.</li><li>               Analyst Donnie Teng cites industry checks showing that Himax will likely win Xiaomi&rsquo;s 3D sensing order in the second half of 2018 with the sensing project starting in 1H18.&nbsp;</li><li>               Teng bases his price target on 22x his FY19 EPS estimate of $0.54, raised from $0.45, and notes that the stock currently trades at 18x the 2019 EPS.&nbsp;</li><li>               Himax shares are&nbsp;<font color='green'>up 3.16%</font>&nbsp;premarket to $9.80.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3297548\" data-linked=\"Nomura Instinet raises himax price target\" data-tweet=\"$HIMX - Nomura Instinet raises himax price target https://seekingalpha.com/news/3297548-nomura-instinet-raises-himax-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3297548-nomura-instinet-raises-himax-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297544\" data-ts=\"1506429035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GHL\" target=\"_blank\">GHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297544-greenhill-up-13-after-announcing-leveraged-recap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Greenhill up 13% after announcing leveraged recap</a></h4><ul><li>Big<a href=\"https://seekingalpha.com/pr/16950280-greenhill-announces-plan-recapitalization-major-share-repurchase\" target=\"_blank\"> capital structure changes </a>are on the way for Greenhill &amp; Co. (NYSE:<a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a>).</li><li>Step one will be to borrow $300M under a Term Loan B structure, with funds (along with $10M in share purchases by both the chairman and CEO) to be used to repay all existing bank debt and buy back up to $235M of common stock.</li><li>The company intends to shortly commence a tender offer for 9M shares (about 30% of the float) for $17 each (vs. last night's close of $14.40).</li><li>Alongside all this will be an elimination of the dividend (currently $0.45 per share, or a 12.5% yield).</li><li>Shares are&nbsp;<font color='green'>up 13.2%</font>&nbsp;premarket to $16.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297544\" data-linked=\"Greenhill up 13% after announcing leveraged recap\" data-tweet=\"$GHL - Greenhill up 13% after announcing leveraged recap https://seekingalpha.com/news/3297544-greenhill-up-13-after-announcing-leveraged-recap?source=tweet\" data-url=\"https://seekingalpha.com/news/3297544-greenhill-up-13-after-announcing-leveraged-recap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297540\" data-ts=\"1506428694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297540-analysts-raise-red-hat-price-targets-after-q2-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts raise Red Hat price targets after Q2 beat</a></h4><ul><li>        Analysts out with Red Hat (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>) price target raises after yesterday&rsquo;s Q2 earnings beat.</li><li>                  Mizuho Securities <a href=\"https://www.streetinsider.com/Analyst+Comments/Red+Hat+%28RHT%29+PT+Raised+to+%24125+at+Mizuho+Securities/13326866.html\" target=\"_blank\">raises</a> its price target from $109 to $125 and maintains a Buy rating.    </li><li>               Analyst Abhey Lamba is bullish on near-term execution and positive on Red Hat&rsquo;s sustained growth momentum.&nbsp;</li><li>                  Lamba raises FY18 EPS estimate from $2.37 to $2.78.    </li><li>               Deutsche Bank <a href=\"https://www.streetinsider.com/Analyst+Comments/Red+Hat+%28RHT%29+PT+Raised+to+%24120+at+Deutsche+Bank+Following+2Q/13327450.html\" target=\"_blank\">raises</a> its price target by $10 to $120 and maintains a Buy rating. &nbsp;&nbsp;</li><li>               Red Hat shares are&nbsp;<font color='green'>up 4.53%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297431-red-hat-shares-4_5-percent-q2-guidance-beats\" target=\"_blank\">Red Hat shares up 4.5% after Q2, guidance beats</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297540\" data-linked=\"Analysts raise Red Hat price targets after Q2 beat\" data-tweet=\"$RHT - Analysts raise Red Hat price targets after Q2 beat https://seekingalpha.com/news/3297540-analysts-raise-red-hat-price-targets-after-q2-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3297540-analysts-raise-red-hat-price-targets-after-q2-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297536\" data-ts=\"1506428194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297536-moleculin-announces-fda-approval-of-annamycin-ind-shares-ahead-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin announces FDA approval of Annamycin IND; shares ahead 28% premarket</a></h4><ul> <li>The FDA OK's Moleculin Biotech's (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>)&nbsp;Investigational New Drug application&nbsp;&#40;IND&#41; for&nbsp;<a href=\"http://www.moleculin.com/technology/annamycin/\" target=\"_blank\">Annamycin</a> in the treatment of relapsed or refractory <a href=\"https://en.wikipedia.org/wiki/Acute_myeloid_leukemia\" target=\"_blank\">Acute Myeloid Leukemia</a>. Clinical trials can now start.</li>  <li>The US IND allows Moleculin to make a submission to Polish authorities necessary for the planned Annamycin clinical trial to be conducted there.</li><li>Shares are up&nbsp;<font color='green'>28%</font>&nbsp;premarket on robust volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297536\" data-linked=\"Moleculin announces FDA approval of Annamycin IND; shares ahead 28% premarket\" data-tweet=\"$MBRX - Moleculin announces FDA approval of Annamycin IND; shares ahead 28% premarket https://seekingalpha.com/news/3297536-moleculin-announces-fda-approval-of-annamycin-ind-shares-ahead-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3297536-moleculin-announces-fda-approval-of-annamycin-ind-shares-ahead-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297537\" data-ts=\"1506427944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDXC\" target=\"_blank\">CDXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297537-chromadexs-niagen-shows-positive-effect-in-early-stage-study-shares-up-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChromaDex&#39;s Niagen shows positive effect in early-stage study; shares up 16% premarket</a></h4><ul><li>Thinly traded micro cap ChromaDex (NASDAQ:<a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a>) is up&nbsp;<font color='green'>16</font><font color='green'>%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16950529-chromadex-announces-top-line-results-second-human-clinical-trial\" target=\"_blank\">announcement </a>of encouraging results from an early-stage study assessing the safety and effect of dietary supplement NIAGEN nicotinamide riboside chloride in 140 healthy volunteers over eight weeks.</li><li>The results showed NIAGEN produced statistically significant increases a co-enzyme called nicotinamide adenine dinucleotide (NAD+) compared to placebo. Levels remained elevated for the duration of the study (participants received daily doses of NIAGEN - 100 mg, 300 mg or 1000 mg).</li><li>The company says NAD+ plays a key role in cellular energy metabolism and mitochondrial function. Levels of NAD+ decrease in normal aging so increasing levels may reduce the metabolic stresses of aging.</li><li>Complete results will be submitted for publication.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297537\" data-linked=\"ChromaDex&#39;s Niagen shows positive effect in early-stage study; shares up 16% premarket\" data-tweet=\"$CDXC - ChromaDex&#39;s Niagen shows positive effect in early-stage study; shares up 16% premarket https://seekingalpha.com/news/3297537-chromadexs-niagen-shows-positive-effect-in-early-stage-study-shares-up-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3297537-chromadexs-niagen-shows-positive-effect-in-early-stage-study-shares-up-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297533\" data-ts=\"1506427636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNGA\" target=\"_blank\">MNGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297533-magnegas-loi-for-gasification-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MagneGas LOI for gasification unit</a></h4><ul><li>MagneGas (NASDAQ:<a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a>) <font color='green'>+13.2%</font> premarket after <a href=\"https://seekingalpha.com/pr/16950629-magnegas-announces-loi-1_9-million-gasification-unit\" target=\"_blank\">receiving</a> a preliminary purchase order for a $1.9M gasification unit.</li><li>In addition, the company announced it plans to form a JV, in which it will hold a 40% minority stake and will include a commitment from a European partner to purchase multiple gasification units from MNGA in the near term.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297533\" data-linked=\"MagneGas LOI for gasification unit\" data-tweet=\"$MNGA $TRNX - MagneGas LOI for gasification unit https://seekingalpha.com/news/3297533-magnegas-loi-for-gasification-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3297533-magnegas-loi-for-gasification-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297528\" data-ts=\"1506427062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKBA\" target=\"_blank\">AKBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297528-akebias-vadadustat-successful-in-mid-stage-study-in-japan-phase-3-planned-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akebia&#39;s vadadustat successful in mid-stage study in Japan, Phase 3 planned; shares ahead 5% premarket</a></h4><ul><li>Thinly traded small cap Akebia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket, albeit on only 139 shares, in response to its <a href=\"https://seekingalpha.com/pr/16950569-akebia-announces-positive-top-line-results-phase-2-study-vadadustat-japanese-patients-non\" target=\"_blank\">announcement </a>of positive results from Japan-based Phase 2 clinical trial assessing vadadustat in patients with anemia associated with non-dialysis-dependent chronic kidney disease &#40;CKD&#41;. The results were consistent with earlier studies. Detailed data will be submitted for presentation at a future medical conference and for publication.</li><li>Topline data from a Phase 2 study in dialysis patients with CKD should be announced by year-end. Phase 3 development in non-dialysis patients will commence about the same time.</li><li>The company has inked a new agreement with commercialization partner Mitsubishi Tanabe Pharma Corporation that grants the latter an option to access data from Akebia's global Phase 3 vadadustrat program in exchange for payments of up to $25M.</li><li><a href=\"http://akebia.com/programs/akb-6548/\" target=\"_blank\">Vadadustat&nbsp;</a>is an inhibitor of hypoxia inducible factor &#40;HIF&#41;-prolyl hydroxylase, an enzyme that promotes the breakdown of HIF proteins. HIF is the primary regulator of the production of red blood cells. The body's natural response to anemia is to increase the level of HIF proteins. It is being developed for the treatment of anemia related to chronic kidney disease.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297528\" data-linked=\"Akebia&#39;s vadadustat successful in mid-stage study in Japan, Phase 3 planned; shares ahead 5% premarket\" data-tweet=\"$AKBA - Akebia&#39;s vadadustat successful in mid-stage study in Japan, Phase 3 planned; shares ahead 5% premarket https://seekingalpha.com/news/3297528-akebias-vadadustat-successful-in-mid-stage-study-in-japan-phase-3-planned-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3297528-akebias-vadadustat-successful-in-mid-stage-study-in-japan-phase-3-planned-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297520\" data-ts=\"1506425488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNCA\" target=\"_blank\">GNCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297520-genocea-bails-on-genital-herpes-vaccine-shifts-to-cancer-vaccines-cuts-workforce-40-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genocea bails on genital herpes vaccine, shifts to cancer vaccines, cuts workforce 40%; shares down 53% premarket</a></h4><ul><li>MIcro cap Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) craters&nbsp;<font color='red'>53%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16950215-genocea-announces-strategic-shift-immuno-oncology-development-neoantigen-cancer-vaccines\" target=\"_blank\">announced </a>strategic shift into neoantigen cancer vaccine development. Its new lead candidate is GEN-009 with an IND planned in Q1 2018 (potential marketing approval is years away). A Phase 1 should be initiated in H1 2018 with initial data expected in H1 2019.</li><li>The company says it is exploring strategic alternatives for former lead candidate GEN-003, an immunotherapy candidate for genital herpes.</li><li>Management also plans to cut 40% of its workforce by month-end.</li><li>Cash and cash equivalents will be sufficient to fund operations into mid-2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280484-genocea-reports-positive-top-line-12-month-phase-2b-data-genminus-003-genital-herpes-shares\" target=\"_blank\">Genocea reports positive top-line 12-month Phase 2b data for GEN-003 in genital herpes; shares ahead 17% premarket</a> (July 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297520\" data-linked=\"Genocea bails on genital herpes vaccine, shifts to cancer vaccines, cuts workforce 40%; shares down 53% premarket\" data-tweet=\"$GNCA - Genocea bails on genital herpes vaccine, shifts to cancer vaccines, cuts workforce 40%; shares down 53% premarket https://seekingalpha.com/news/3297520-genocea-bails-on-genital-herpes-vaccine-shifts-to-cancer-vaccines-cuts-workforce-40-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3297520-genocea-bails-on-genital-herpes-vaccine-shifts-to-cancer-vaccines-cuts-workforce-40-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297518\" data-ts=\"1506425307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBRA\" target=\"_blank\">SBRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297518-sabra-healthminus-6-transitions-to-version-3_0-raises-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sabra Health -6% as it transitions to version 3.0, raises capital</a></h4><ul><li>The company last night <a href=\"https://seekingalpha.com/pr/16950203-sabra-quickly-moves-sabra-2_0-ccp-acquisition-sabra-3_0-follows-announcement-371-million\" target=\"_blank\">announced the closing</a> of the sale/leaseback of 21 of its 24 skilled nursing/transitional care facilities for $378M. The remaining three are seen closing before year-end for $52M.</li><li>Sabra (NASDAQ:<a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a>) also put on the block its remaining 43 facilities leased to Genesis Healthcare, with the sales seen closing next year for $425M-$475M.</li><li>Sabra 3.0 will have an enterprise value of $6.8B (vs. $2.8B at the end of Q2). Top 5 relationship concentration will drop to 40% from 70% (Genesis moves to 0% from 36%).</li><li>2018 normalized AFFO is now seen at $2.33-$2.39 per share vs. $2.41-$2.47 previously.</li><li>The company <a href=\"https://seekingalpha.com/pr/16950365-sabra-health-care-reit-prices-public-offering-16000-000-shares-common-stock\" target=\"_blank\">priced a 16M share offering</a> at $21 each. Shares are&nbsp;<font color='red'>down 6%&nbsp;</font>this morning to $21.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297518\" data-linked=\"Sabra Health -6% as it transitions to version 3.0, raises capital\" data-tweet=\"$SBRA - Sabra Health -6% as it transitions to version 3.0, raises capital https://seekingalpha.com/news/3297518-sabra-healthminus-6-transitions-to-version-3_0-raises-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3297518-sabra-healthminus-6-transitions-to-version-3_0-raises-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297516\" data-ts=\"1506424759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXON\" target=\"_blank\">AXON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297516-axovants-intepirdine-fails-to-beat-placebo-in-late-stage-alzheimers-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axovant&#39;s intepirdine fails to beat placebo in late-stage Alzheimer&#39;s study</a></h4><ul><li>Shareholders in Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>) face an ugly day today after the company <a href=\"https://seekingalpha.com/pr/16950585-axovant-announces-negative-topline-results-intepirdine-phase-3-mindset-trial-alzheimers\" target=\"_blank\">announced </a>a negative outcome in a Phase 3 clinical trial, MINDSET, assessing intepirdine in patients with mild-to-moderate Alzheimer's disease &#40;AD&#41; on background donepezil therapy (Eisai's ARICEPT).</li><li>Intepirdine failed to beat placebo as measured by improvement in cognition or measures of daily living as determined by two scales called ADAS-Cog and ADCS-ADL after 24 weeks of treatment.</li><li>The only endpoint where intepirdine showed a treatment benefit over placebo was in a scale called CIBIC (Clinician Interview-Based Impression of Change).</li><li>Topline data from the Phase 2b HEADWAY study assessing intepirdine in patients with dementia with Lewy bodies, a Fast Track-designated indication, should be available by year-end.</li><li>Intepirdine is an antagonist of the 5HT6 receptor which promotes the release of acetylcholine, a neurotransmitter essential for normal cognition.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297507-axovant-sciences-halted-pending-news\" target=\"_blank\">Axovant Sciences halted pending news</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297516\" data-linked=\"Axovant&#39;s intepirdine fails to beat placebo in late-stage Alzheimer&#39;s study\" data-tweet=\"$AXON $AXON-OLD - Axovant&#39;s intepirdine fails to beat placebo in late-stage Alzheimer&#39;s study https://seekingalpha.com/news/3297516-axovants-intepirdine-fails-to-beat-placebo-in-late-stage-alzheimers-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3297516-axovants-intepirdine-fails-to-beat-placebo-in-late-stage-alzheimers-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297513\" data-ts=\"1506424166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297513-ascena-retail-rallies-after-topping-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail rallies after topping estimates</a></h4><ul> <li>Ascena (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>) soars after besting estimates with its <a href=\"https://seekingalpha.com/pr/16950155-ascena-retail-group-inc-reports-fourth-quarter-full-year-fiscal-2017-results-provides\" target=\"_blank\">FQ4</a> report.</li> <li>Comparable sales fell 4% during the quarter to top the 8.6% slide estimated by analysts. Catherines was the only brand to show positive comparable sales growth.</li> <li>The company cited a \"moderate\" easing of store traffic headwinds, but said mall conditions are still challenging with traffic down at a mid-single digit rate. \"While comp sales performance was several points better than our guide, we were not pleased with the results, and we will not be satisfied until we deliver positive, sustained enterprise-level comp sales,\" notes CEO David Jaffe.</li> <li>Gross margin fell 10 bps to 57.4% of sales during the quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297420-ascena-retail-group-beats-0_08-beats-revenue\" target=\"_blank\">Ascena Retail Group beats by $0.08, beats on revenue</a> (Sept. 25)</li> <li>Shares of Ascena Retail are <font color='green'>up 17.05%</font> in premarket trading to 2.54.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297513\" data-linked=\"Ascena Retail rallies after topping estimates\" data-tweet=\"$ASNA - Ascena Retail rallies after topping estimates https://seekingalpha.com/news/3297513-ascena-retail-rallies-after-topping-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3297513-ascena-retail-rallies-after-topping-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297507\" data-ts=\"1506423629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXON\" target=\"_blank\">AXON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297507-axovant-sciences-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axovant Sciences halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297507\" data-linked=\"Axovant Sciences halted pending news\" data-tweet=\"$AXON $AXON-OLD - Axovant Sciences halted pending news https://seekingalpha.com/news/3297507-axovant-sciences-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3297507-axovant-sciences-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":71,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}